{
    "cancer_info": {
        "cancer_name": "Uterine Neoplasms"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "History and physical exam",
            "CBC",
            "Liver function tests",
            "Renal function tests",
            "CA-125 (if extrauterine disease suspected)",
            "Pelvic MRI (preferred for local staging)",
            "CT abdomen/pelvis",
            "PET-CT for suspected metastasis",
            "Endometrial biopsy/D&C with expert review",
            "HER2 IHC ± FISH",
            "ER/PR testing",
            "MMR/IHC or MSI testing",
            "POLE exonuclease domain sequencing",
            "p53 IHC",
            "Comprehensive genomic profiling (NTRK, MSI, RET fusions, TMB)",
            "FISH/RNA-seq for JAZF1-PHF1/EPC1 fusions (LG-ESS)",
            "IHC for CD10, cyclin D1, BCOR (HG-ESS)",
            "IHC for SMARCA4 (BRG1) (UUS)",
            "FISH for FOXO1 fusions (RMS)",
            "Peritoneal washings",
            "Sentinel lymph node (SLN) mapping with ultrastaging",
            "Genetic counseling for Lynch syndrome",
            "Transvaginal ultrasound (if MRI contraindicated)"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Stage IA (Endometrial Carcinoma)",
            "risk_group": "Low risk (Grade 1-2, no LVSI)",
            "treatment_plans": [
                {
                    "treatment_line": "Adjuvant",
                    "patient_subgroup": "Endometrial carcinoma",
                    "plan_name": "Observation",
                    "plan_details": "No adjuvant therapy",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage IA (Endometrial Carcinoma)",
            "risk_group": "Intermediate risk (Grade 3)",
            "treatment_plans": [
                {
                    "treatment_line": "Adjuvant",
                    "patient_subgroup": "Endometrial carcinoma",
                    "plan_name": "Vaginal brachytherapy",
                    "plan_details": "± EBRT if LVSI+/age ≥70",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage IB (Endometrial Carcinoma)",
            "risk_group": "Intermediate risk (Grade 1-2)",
            "treatment_plans": [
                {
                    "treatment_line": "Adjuvant",
                    "patient_subgroup": "Endometrial carcinoma",
                    "plan_name": "Vaginal brachytherapy",
                    "plan_details": "Preferred over observation",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage IB (Endometrial Carcinoma)",
            "risk_group": "High risk (Grade 3)",
            "treatment_plans": [
                {
                    "treatment_line": "Adjuvant",
                    "patient_subgroup": "Endometrial carcinoma",
                    "plan_name": "Vaginal brachytherapy + EBRT",
                    "plan_details": "± systemic therapy",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Other Recommended"
                }
            ]
        },
        {
            "staging_criteria": "Stage II (Endometrial Carcinoma)",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "treatment_line": "Adjuvant",
                    "patient_subgroup": "Endometrial carcinoma",
                    "plan_name": "EBRT ± vaginal brachytherapy",
                    "plan_details": "± systemic therapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage III/IV (Endometrial Carcinoma)",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "dMMR/MSI-H tumors",
                    "plan_name": "Carboplatin/paclitaxel + pembrolizumab/dostarlimab",
                    "plan_details": "Immunotherapy combination",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "HER2+ serous carcinoma",
                    "plan_name": "Carboplatin/paclitaxel + trastuzumab",
                    "plan_details": "Targeted therapy combination",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Second-line",
                    "patient_subgroup": "pMMR tumors",
                    "plan_name": "Lenvatinib + pembrolizumab",
                    "plan_details": "Anti-angiogenesis + immunotherapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage I (Uterine Sarcomas)",
            "risk_group": "Low risk (LG-ESS/adenosarcoma without SO)",
            "treatment_plans": [
                {
                    "treatment_line": "Adjuvant",
                    "patient_subgroup": "Uterine sarcoma",
                    "plan_name": "Surgery ± anti-estrogen therapy",
                    "plan_details": "Aromatase inhibitors for ER/PR+ tumors",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Other Recommended"
                }
            ]
        },
        {
            "staging_criteria": "Stage II-IV (Uterine Sarcomas)",
            "risk_group": "High risk (LMS, HG-ESS, UUS)",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "Leiomyosarcoma",
                    "plan_name": "Doxorubicin-based regimens",
                    "plan_details": "Gemcitabine/docetaxel or doxorubicin/trabectedin",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Second-line",
                    "patient_subgroup": "NTRK fusion-positive sarcomas",
                    "plan_name": "TRK inhibitors",
                    "plan_details": "Larotrectinib/entrectinib/repotrectinib",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Fertility preservation",
            "risk_group": "Stage IA Grade 1-2 endometrioid",
            "treatment_plans": [
                {
                    "treatment_line": "Primary",
                    "patient_subgroup": "Premenopausal patients",
                    "plan_name": "Progestin-based therapy",
                    "plan_details": "Levonorgestrel IUD ± systemic progestins",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Useful in Certain Circumstances"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "MMR/MSI-H: Predicts response to immunotherapy (pembrolizumab/dostarlimab); POLE mutations: Ultramutated, favorable prognosis allowing therapy de-escalation; p53 abnormal: Associated with aggressive serous/carcinosarcoma, mandates HER2 testing; HER2 overexpression: Targets trastuzumab in serous carcinoma; NTRK fusions: Indicates TRK inhibitor therapy (larotrectinib/entrectinib); TMB-H (≥10 mut/Mb): Eligibility for pembrolizumab in recurrent disease; BRCA mutations: PARP inhibitor sensitivity (olaparib)"
    },
    "guideline_id": "（2025.V1）NCCN临床实践指南：子宫肿瘤.txt"
}